Zydus Lifesciences Hits 52-Week High, Rated 'Buy' by MarketsMOJO

Zydus Lifesciences, a leading pharmaceutical company in the largecap industry, has recently hit a 52-week high on February 15, 2024. This positive trend has been reflected in the stock call given by MarketsMOJO, which has rated the stock as a 'Buy'. The stock has been performing well, with a consecutive gain for the last 6 days and a rise of 10.22% in this period. Today, the stock has reached a new 52-week and all-time high of Rs. 873. This is in line with the performance of the sector and shows the strong growth potential of Zydus Lifesciences. Moreover, the stock has been trading in a narrow range of Rs. 4.25, indicating stability and a positive outlook for the company. It is also worth noting that Zydus Lifesciences is currently trading higher than its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, further reinforcing its strong performance. In comparison to the Sensex, Zydus Lifesciences has shown an impressive 1-year performance of 85.36%, while the Sensex has only grown by 17.32%. This showcases the company's ability to outperform the market and deliver strong returns for its investors. With its consistent growth and positive outlook, Zydus Lifesciences is definitely a stock to watch out for in the pharma industry. Investors can consider adding it to their portfolio for long-term gains.